Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests. The drug, which contains the active ingredient semaglutide, works by reducing food ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

A new study has found that a drug called semaglutide could help improve heart health in people who are overweight or obese, ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Landmark' data has revealed a popular weight loss medicine slashes the risk of heart attack, stroke or heart disease death ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

with the established benefits of semaglutide for diabetes, obesity and heart disease, this is a major step forward for patients with MASH, who often have obesity and diabetes and are at risk for ...

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed pounds, data suggests. The drug, which contains the active ingredient semaglutide, works by reducing food ...